Ripretinib Continues to Provide Meaningful Clinical Benefit in Heavily Pretreated GIST
OncLive,
John R. Zalcberg, MBBS, PhD, discusses the INVICTUS trial examining ripretinib in patients with heavily pretreated…
1540P Ripretinib as ≥4th-line treatment in patients with advanced gastrointestinal stromal tumor: Long-term update from the phase III INVICTUS study
Overview of attention for article published in Annals of Oncology, September 2021
Altmetric Badge
About this Attention Score
-
In the top 25% of all research outputs scored by Altmetric
-
High Attention Score compared to outputs of the same age (82nd percentile)
-
Good Attention Score compared to outputs of the same age and source (67th percentile)
Readers on
- mendeley
- 10 Mendeley